MedTrace Logo

STUDY OF PREFERENCES IN MEN FACED WITH THE DIFFERENT TREATMENT OPTIONS FOR LOCALIZED PROSTRATE CANCER WITH A GOOD OR INTERMEDIATE PROGNOSIS

NCT02080793 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 652

Last updated 2019-05-07

No results posted yet for this study

Summary

This study will be based on two questionnaires

1. One specific questionnaire that has already been developed from social sciences interviews conducted in men who have been treated for localized prostrate cancer, with a good or intermediate prognosis. This questionnaire comprises 11 pairs of scenarios. Each scenario gathers in a random manner, the modalities of 7 possible characteristics of the management strategy for localized prostrate cancer, with a good or intermediate prognosis:

* the risk of death at 5 years (modalities: 5%, 15%),
* the risk of impotence (modalities: 0%, 25%, 50%, 75%),
* the presence of urinary leaks (modalities: no protection during the day, one protection pad per day, several protection pads per day),
* the duration and frequency of care provided (modalities: 2 days of care in your whole life, 7 days of care in your whole life, 5 half-days of care per week for 8 weeks, every 3 months for 2 years then every 6 months for life),
* ablation of the prostate (modalities: Yes, No),
* the existence of possible treatments in case of aggravation or recurrence (modalities: Yes, No),
* the nature of the technology used (modalities: innovative technology, standard technology).

The objective is to ask each participant of the study for each pair of scenarios, to choose from the two scenarios (binary-choice survey), the scenario he prefers.
2. The "Spielberger Inventory Trait" scale to evaluate stable characteristics in the propensity to anxiety in study participants.

Conditions

  • Patients Seen at a Urology Consultation

Interventions

OTHER

Questionnaire

Sponsors & Collaborators

  • Centre Hospitalier Universitaire Dijon

    lead OTHER

Study Design

Purpose
OTHER

Eligibility

Min Age
50 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-25
Primary Completion
2016-06-28

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02080793 on ClinicalTrials.gov